Tohru Ohmori

Institute of Molecular Oncology, Showa University

Affiliated withShowa University Showa University School of Medicine

Research Area

Biography

Tohru Ohmori has not added Biography.
If you are Tohru Ohmori and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 2	Year
Publication title Cited by 4	2017
Publication title Cited by 3	2019

Other Publications

Article	Year
Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in ... International journal of cancer\| PubMed ID: 11857424	2002
Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands)\| PubMed ID: 12499100	2003
Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung cancer (Amsterdam, Netherlands)\| PubMed ID: 12781433	2003
Patients preferences in chemotherapy for advanced non-small-cell lung cancer. Internal medicine (Tokyo, Japan)\| PubMed ID: 15750269	2005
The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer. Cancer chemotherapy and pharmacology\| PubMed ID: 16331494	2006
Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 16361577	2005
Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands)\| PubMed ID: 16563558	2006
Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer. Cancer chemotherapy and pharmacology\| PubMed ID: 17273827	2007
Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer. Cancer chemotherapy and pharmacology\| PubMed ID: 17589845	2008
Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl. Anticancer research\| PubMed ID: 17695511	2007
Effectiveness of intensive follow-up after response in patients with small cell lung cancer. Lung cancer (Amsterdam, Netherlands)\| PubMed ID: 17900754	2008
Patient willingness to undergo chemotherapy and thoracic radiotherapy for locally advanced non-small cell lung cancer. Psycho-oncology\| PubMed ID: 18942662	2009
Phase II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer. Anticancer research\| PubMed ID: 19443395	2009
Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines. Anticancer research\| PubMed ID: 19528497	2009
Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer. Oncology reports\| PubMed ID: 19787234	2009
EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Frontiers in bioscience (Landmark edition)\| PubMed ID: 20036807	2010
[Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer]. Gan to kagaku ryoho. Cancer & chemotherapy\| PubMed ID: 20154478	2010
The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer. Oncology research\| PubMed ID: 20377135	2010
Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer? Lung cancer (Amsterdam, Netherlands)\| PubMed ID: 20537424	2011
Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer. Cancer chemotherapy and pharmacology\| PubMed ID: 20556612	2011
Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer. Lung cancer (Amsterdam, Netherlands)\| PubMed ID: 21277039	2011
Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer. European journal of cancer (Oxford, England : 1990)\| PubMed ID: 21458256	2011
[The mechanisms of resistance to EGFR-TKIs and challenges to overcome resistance in EGFR mutant non-small cell lung cancer]. Gan to kagaku ryoho. Cancer & chemotherapy\| PubMed ID: 22705678	2012
MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer\| PubMed ID: 22722827	2012
Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer. Oncology research\| PubMed ID: 23193919	2012
Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease. Anticancer research\| PubMed ID: 23225454	2012
Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer. Molecular and clinical oncology\| PubMed ID: 24772308	2014
Prognostic impact of the number of viable circulating cells with high telomerase activity in gastric cancer patients: a prospective study. International journal of oncology\| PubMed ID: 24788213	2014
Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands)\| PubMed ID: 26898617	2016
Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. Molecular cancer therapeutics\| PubMed ID: 27612490	2016
Long-term prognostic impact of circulating tumour cells in gastric cancer patients. World journal of gastroenterology\| PubMed ID: 28028372	2016
Change in number and size of circulating tumor cells with high telomerase activity during treatment of patients with gastric cancer. Oncology letters\| PubMed ID: 28105179	2016
Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. Molecular cancer research : MCR\| PubMed ID: 28289161	2017
Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. International journal of molecular sciences\| PubMed ID: 29140271	2017
and Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in . Molecular cancer therapeutics\| PubMed ID: 30322949	2019
Receptor Tyrosine Kinase-Targeted Cancer Therapy. International journal of molecular sciences\| PubMed ID: 30404198	2018